Press Releases

November 30, 2021

Notal Vision Monitoring Center Reports Completion of 10 Million Foresee Home AMD Home Monitoring Tests

October 12, 2021

Notal Vision Reports Results of First US Home OCT Feasbility Study with Patient Self-operated Device

July 13, 2021

Notal Vision announces publication of first prospective longitudinal pilot study of daily self-imaging with patient-operated Home OCT in wet AMD patients

June 1, 2021

Notal Vision raises up to $60 million to support development of its Home OCT technology and commercial growth of its ForeseeHome AMD Monitoring Program

April 6, 2021

ForeseeHome AMD home monitoring real-world data analysis demonstrates substantial benefit for patients’ vision

SCANLY Home OCT FDA Intended Use

SCANLY Home OCT has not been approved by FDA for use other than described in the following Intend Use: The Notal Vision Home Optical Coherence Tomography (OCT) System is an Artificial Intelligence (AI)-based Home Use device indicated for visualization of intraretinal and subretinal hypo-reflective spaces in a 10 by 10-degrees area centered on the point of fixation of eyes diagnosed with neovascular age-related macular degeneration (NV-AMD). In addition, it provides segmentation and an estimation of the volume of hypo-reflective spaces. The Notal Home OCT device is intended for imaging at home between regularly scheduled clinic assessments and not intended to be used to make treatment decisions or replace standard-of care regularly scheduled examinations and clinical testing as needed, including in-office imaging and assessments for changes in vision, by an ophthalmologist.

See also Warnings and Precautions.

ForeseeHome FDA Intended Use

ForeseeHome has not been approved by FDA for use other than described in the following Indication for Use: The ForeseeHome is intended for use in the detection and characterization of central and paracentral metamorphopsia (visual distortion) in patients with age-related macular degeneration as an aid in monitoring progression of disease factors causing metamorphopsia including, but not limited to choroidal neovascularization (CNV). It is intended to be used at home for patients with stable fixation.

Media enquiries? Reach out to our Media Contact